Medical device company Dynatronics Corporation (NASDAQ:DYNT) disclosed on Tuesday its net income of USD14,000 for Q2 fiscal 2018 ended 31 December 2017.
This is compared with a net loss of USD95,000 for the quarter ended 31 December 2016.
Net sales of USD18.1m were recorded for the Q2 fiscal 2018 ended 31 December 2017, up 107.5% over net sales of USD8.7m in the same period of the prior year.
Gross profit of USD5.8m was announced for the Q2 fiscal 2018 ended 31 December 2017, a rise of 87.7% versus USD3.1m the same prior year quarter.
The company added that the rise in net sales, gross profit and net income were attributable to its acquisitions of Hausmann and Bird & Cronin in the past year.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon